Cyteir Therapeutics Past Earnings Performance
Past criteria checks 0/6
Cyteir Therapeutics's earnings have been declining at an average annual rate of -21.6%, while the Biotechs industry saw earnings growing at 15.3% annually.
Key information
-21.6%
Earnings growth rate
80.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -26.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Is Cyteir Therapeutics (NASDAQ:CYT) In A Good Position To Deliver On Growth Plans?
Oct 25
Cyteir Therapeutics GAAP EPS of -$0.34
Aug 08Cyteir Therapeutics (NASDAQ:CYT) Is In A Good Position To Deliver On Growth Plans
Jul 21Here's Why We're Not Too Worried About Cyteir Therapeutics' (NASDAQ:CYT) Cash Burn Situation
Apr 21Companies Like Cyteir Therapeutics (NASDAQ:CYT) Are In A Position To Invest In Growth
Jan 06We're Not Very Worried About Cyteir Therapeutics' (NASDAQ:CYT) Cash Burn Rate
Sep 21Cyteir Therapeutics closes lower on first day of trading
Jun 18Revenue & Expenses BreakdownBeta
How Cyteir Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -33 | 12 | 22 |
| 30 Jun 23 | 0 | -41 | 13 | 27 |
| 31 Mar 23 | 0 | -44 | 14 | 31 |
| 31 Dec 22 | 0 | -46 | 15 | 34 |
| 30 Sep 22 | 0 | -49 | 15 | 35 |
| 30 Jun 22 | 0 | -50 | 15 | 35 |
| 31 Mar 22 | 0 | -49 | 14 | 35 |
| 31 Dec 21 | 0 | -42 | 11 | 31 |
| 30 Sep 21 | 0 | -36 | 9 | 39 |
| 30 Jun 21 | 0 | -29 | 6 | 31 |
| 31 Mar 21 | 0 | -22 | 5 | 22 |
| 31 Dec 20 | 0 | -21 | 4 | 17 |
| 31 Dec 19 | 0 | -15 | 3 | 0 |
Quality Earnings: CYTT is currently unprofitable.
Growing Profit Margin: CYTT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CYTT is unprofitable, and losses have increased over the past 5 years at a rate of 21.6% per year.
Accelerating Growth: Unable to compare CYTT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYTT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: CYTT has a negative Return on Equity (-26.57%), as it is currently unprofitable.